SARS-CoV-2 ORF7a drives mitochondrial dysfunction via PDK4 activation and complex I inhibition.

Publication date: Jul 28, 2026

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection reprograms host metabolism to favor viral replication and immune evasion, yet the contribution of accessory proteins remains poorly defined. Here, we characterize the metabolic effects of the SARS-CoV-2 accessory protein ORF7a. Lentiviral expression of ORF7a in human lung epithelial (A549) and monocytic (THP1) cells, combined with integrated transcriptomic, proteomic, and metabolomic analyses, revealed marked dysregulation of glucose and lipid metabolism. ORF7a impaired mitochondrial oxidative phosphorylation, reducing basal and maximal respiration, inducing mitochondrial depolarization, and increasing reactive oxygen species. Mechanistically, ORF7a upregulated pyruvate dehydrogenase kinase 4 (PDK4), enhancing phosphorylation of the pyruvate dehydrogenase complex and suppressing pyruvate oxidation. However, pharmacological PDK4 inhibition failed to restore respiratory function. High-resolution respirometry identified complex I dysfunction, while Blue Native-PAGE revealed defective assembly of respiratory supercomplexes. Together, these findings demonstrate that ORF7a disrupts mitochondrial metabolism through enzymatic regulation and destabilization of the respiratory chain, highlighting mitochondria as a target of SARS-CoV-2-induced metabolic reprogramming.

Open Access PDF

Concepts Keywords
Coronavirus complex I dysfunction
Destabilization CP: microbiology
Glucose metabolic reprogramming
Pharmacological mitochondrial dysfunction
Transcriptomic ORF7a
oxidative phosphorylation
respiratory chain supercomplexes
SARS-CoV-2

Semantics

Type Source Name
disease MESH mitochondrial dysfunction
disease MESH Severe acute respiratory syndrome
disease MESH infection
pathway REACTOME Metabolism
pathway KEGG Viral replication
drug DRUGBANK Dextrose unspecified form
pathway KEGG Oxidative phosphorylation
drug DRUGBANK Isoxaflutole
pathway REACTOME Glycolysis
disease MESH Zoonoses
drug DRUGBANK Linoleic acid
disease MESH SARS CoV 2 infection
disease MESH acute respiratory distress syndrome
disease MESH long COVID
disease MESH viral infections
pathway KEGG Fatty acid biosynthesis
drug DRUGBANK Hyaluronic acid
disease MESH hypoxia
drug DRUGBANK Oxygen
disease MESH mROS
disease MESH inflammation
pathway REACTOME Apoptosis
drug DRUGBANK Calcium
drug DRUGBANK ATP
drug DRUGBANK Adenosine 5′-phosphosulfate
disease MESH ered
drug DRUGBANK Dichloroacetic Acid
pathway REACTOME Nucleotide biosynthesis
pathway KEGG Nitrogen metabolism
pathway REACTOME Urea cycle
pathway REACTOME Pentose phosphate pathway
disease MESH PPP
pathway REACTOME mRNA Splicing
pathway KEGG Fatty acid degradation
drug DRUGBANK Phosphate ion
drug DRUGBANK Coenzyme A
disease MESH PLS

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *